Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Halaven in Metastatic HR+ Breast Cancer
NCT03051659Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Hormone-Receptor-Positive Breast Cancer, sponsored by Dana-Farber Cancer Institute. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03051659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051659.